AccuPulse

Executive Summary

AccuPulse is a privately held Chinese medical device company specializing in minimally invasive catheter-based systems for cardiovascular and respiratory interventions. The company differentiates itself by integrating real-time imaging and data analytics into its therapeutic devices, aiming to enhance procedural accuracy and patient outcomes. Founded in 2015 and headquartered in Shenzhen, AccuPulse has reached the commercial stage with a workforce of 200–500 employees. While the company has not disclosed total funding or valuation, its focus on high-growth areas like cardiovascular and respiratory disease positions it well within China's expanding medtech market. The combination of proprietary technology and a growing domestic demand for advanced interventional solutions suggests potential for revenue growth and market share expansion.

Upcoming Catalysts (preview)

• Q3 2026NMPA approval for next-generation catheter system70% success
• TBDStrategic partnership with major hospital network in China60% success
• Q3 2026Publication of pivotal clinical trial data for respiratory intervention device50% success